Insider Selling: Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Insider Sells 10,507 Shares of Stock

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) insider Jeffrey Dierks sold 10,507 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $37.01, for a total transaction of $388,864.07. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Jeffrey Dierks also recently made the following trade(s):

• On Tuesday, October 29th, Jeffrey Dierks sold 21,496 shares of Harmony Biosciences stock. The shares were sold at an average price of $40.47, for a total value of $869,943.12.

Harmony Biosciences Trading Up 4.4 %

HRMY stock traded up $1.61 on Thursday, reaching $38.54. The company’s stock had a trading volume of 992,496 shares, compared to its average volume of 513,855. Harmony Biosciences Holdings, Inc. has a 12-month low of $28.14 and a 12-month high of $41.61. The firm has a market cap of $2.20 billion, a PE ratio of 18.27, a PEG ratio of 0.49 and a beta of 0.78. The business has a fifty day simple moving average of $34.26 and a two-hundred day simple moving average of $34.76. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $0.79 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.15. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The firm had revenue of $186.00 million for the quarter, compared to analysts’ expectations of $184.07 million. During the same period in the previous year, the firm posted $0.63 EPS. The business’s revenue for the quarter was up 16.0% compared to the same quarter last year. As a group, research analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.42 EPS for the current year.

Analysts Set New Price Targets

HRMY has been the subject of a number of recent analyst reports. Raymond James reaffirmed an “outperform” rating and set a $40.00 target price on shares of Harmony Biosciences in a report on Thursday, October 10th. Mizuho upped their target price on shares of Harmony Biosciences from $42.00 to $52.00 and gave the stock an “outperform” rating in a report on Thursday, October 10th. Oppenheimer reissued an “outperform” rating and issued a $59.00 price target (up from $56.00) on shares of Harmony Biosciences in a report on Wednesday, October 30th. Cantor Fitzgerald upped their price target on shares of Harmony Biosciences from $51.00 to $58.00 and gave the stock an “overweight” rating in a report on Wednesday, October 30th. Finally, HC Wainwright restated a “buy” rating and set a $75.00 target price on shares of Harmony Biosciences in a research report on Thursday. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $55.00.

Institutional Trading of Harmony Biosciences

Several institutional investors have recently bought and sold shares of the company. Pacer Advisors Inc. increased its position in shares of Harmony Biosciences by 0.6% during the second quarter. Pacer Advisors Inc. now owns 2,509,609 shares of the company’s stock valued at $75,715,000 after acquiring an additional 14,695 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Harmony Biosciences by 13.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 956,785 shares of the company’s stock worth $28,871,000 after purchasing an additional 112,197 shares in the last quarter. American Century Companies Inc. raised its stake in shares of Harmony Biosciences by 53.7% in the second quarter. American Century Companies Inc. now owns 681,536 shares of the company’s stock worth $20,562,000 after purchasing an additional 238,140 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in shares of Harmony Biosciences by 27.1% during the third quarter. Massachusetts Financial Services Co. MA now owns 660,391 shares of the company’s stock valued at $26,416,000 after purchasing an additional 140,690 shares in the last quarter. Finally, Renaissance Technologies LLC raised its position in Harmony Biosciences by 56.7% in the 2nd quarter. Renaissance Technologies LLC now owns 595,800 shares of the company’s stock worth $17,975,000 after buying an additional 215,700 shares during the last quarter. 86.23% of the stock is owned by hedge funds and other institutional investors.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.